Serenity Pharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: Brooklyn NY United States (2006)
Status: Acquired by Acerus Pharmaceuticals Corporation (2022) → now Bausch Health Companies (2010)

Organization Overview

First Clinical Trial
2009
NCT00937378
First Marketed Drug
2017
desmopressin (ddavp)
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SERENITY PHARMS LLC

Active Ingredients

Marketed Drugs (1)

desmopressin (ddavp) (2017)

Drugs in Phase 3 Trials (1)

desmopressin (ddavp) (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Nocturia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 1